Abstract: A new method of treatment is disclosed for a vascular obstructive lesion resulting from restricted blood circulation, characterized by an erythrocyte pathology, in an effected animal subject. The new method involves the administration of 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinolinium-theophylli ne-7-acetat e, in a dosage and at a rate sufficient to maintain a blood concentration of at least 0.5 to at most 3 .gamma./ml, calculated on the basis of 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline.

Abstract: The invention relates to new 6-fluoro-7-chloro-1-methylamino-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid/boric acid anhydrides of the general Formula I ##STR1## (wherein R and R.sup.1 stand for halogen; an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen; or an aromatic acyloxy group comprising 7-11 carbon atoms).The new compounds of the general Formula I are valuable intermediates useful in the preparation of the antibacterial agent 6-fluoro-1-methylamino-7-(4-methyl-piperazino)-4-oxo-1,4-dihydro-quinoline -3- carboxylic acid.The new compounds of the general Formula I may be prepared by reacting a compound of the Formula II ##STR2## or a compound of the general Formula III ##STR3## (wherein R.sup.2 stands for alkyl comprising 1-4 carbon atoms) with hydrogen fluoro borate of the Formula IVHBF.sub.4 /IV/or a borone trihalide of the general Formula VBX.sub.

Abstract: The invention relates to a process for the preparation of compounds of the Formula I ##STR1## (wherein R and R.sup.1 stand for an aliphatic acyloxy group comprising 2-5 carbon atoms and optionally substituted by halogen or for an aromatic acyloxy group comprising 7-11 carbon atoms), which comprises reacting a compound of the general Formula II ##STR2## (wherein R.sup.2 stands for hydrogen or alkyl comprising 1-4 carbon atoms) with a boron derivative of the Formula III ##STR3## (wherein R.sup.3, R.sup.4 and R.sup.5 stand for an alkyl group comprising 1-4 carbon atoms and optionally substituted by halogen or for an aryl group comprising 6-10 carbon atoms).The new compounds of the general Formula I are useful pharmaceutical intermediates.

Abstract: The invention relates to new compounds of the Formula I ##STR1## wherein R.sup.2 stands for hydrogen or C.sub.1-4 alkyl; andR.sup.3 represents C.sub.1-4 alkyl or a group of the Formula R.sup.4 --(CH.sub.2).sub.n -- wherein n is 1 or 2;R.sup.4 represents C.sub.1 to C.sub.4 alkoxy-carbonylor a group of the Formula II ##STR2## and R.sup.6 and R.sup.7 stand for hydrogen or C.sub.1-4 alkoxy; orR.sup.2 and R.sup.3 together may form a group of the Formula --(CH.sub.2).sub.2 --O--CH.sub.2).sub.2 -- with the proviso that R.sup.2 and R.sup.3 do not both stand for methyl, and salts thereof and a process for the preparation of the same.

Abstract: This invention relates to salts of primycin formed with an organic acid--preferably a C.sub.1-16 aliphatic carboxylic acid, a halogenated carboxylic acid, an aliphatic dicarboxylic acid, an aromatic carboxylic acid, a substituted aromatic carboxylic acid or an organic sulfonic acid--or an inorganic acid--preferably a hydrohalogenic acid.There is furtheron provided a process for the preparation of new primycin salts which comprises reacting a suspension of primycin sulfate formed with an aliphatic alcohol containing 1-4 carbon atoms with a barium salt.The new primycin salts of the present invention possess excellent antibiotic properties.

Abstract: Fungicidal or insecticidal seed dressings characterized by a water content substantially greater than that of the carrier vehicle providing homogeneous coating.

Abstract: The invention relates to novel pyrimido [5,4-b][1,4]oxazine derivatives of the formula (I), and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## wherein R.sup.1 stands for a C.sub.1-4 alkyl group;R.sup.2 stands for hydrogen or halogen or an azido group or an --NR.sup.5 R.sup.6 group, whereinR.sup.5 represents hydrogen or a benzyl group, or a C.sub.1-4 alkyl group unsubstituted or substituted by a hydroxyl group,R.sup.6 stands for hydrogen, an amino group, a C.sub.3-6 cycloalkyl group, a straight or branched-chain C.sub.1-4 alkyl group optionally substituted by a hydroxyl, mercapto, aminocarbonyl, furyl, 2-benzo[1,4]dioxanyl, di(C.sub.1-4 alkyl)amino group or by a phenyl or phenoxy group optionally mono- or polysubstituted by halogen or C.sub.1-4 alkoxy group (s) or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C.

Abstract: The invention relates to new 7-oxo-PGI.sub.2 -ephedrine salt analogues of the Formula I ##STR1## wherein A stands for --(CH.sub.2).sub.2 --, cis or trans --CH.dbd.CH-- or --C.tbd.C--;R.sup.1 is lower alkyl or hydrogen;B represents a chemical bond, --CH.sub.2 -- or --CR.sup.2 R.sup.3 ;R.sup.2 stands for lower alkyl or hydrogen;R.sup.3 represents lower alkyl or hydrogen;X is a chemical bond, --O-- or --CH.sub.2 --;R.sup.4 stands for C.sub.1-6 alkyl, C.sub.4-7 cycloalkyl, C.sub.1-6 fluoroalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, phenyl, substituted phenyl or heteroaryl.The salts of the Formula I show the same pharmacological profile as the sodium salt of PGI.sub.2, they inhibit blood aggregation and the secretion of gastric acid, are useful in the prevention of anginal attacks.

Abstract: A new process is disclosed for preparing a compound of the formula (I) ##STR1## wherein R is C.sub.1 to C.sub.5 alkyl; which comprises reducing a compound of the formula (II) ##STR2## or salt thereof wherein A is --SO.sub.2 X, --SOH, --SOA.sup.1, or --SA.sup.1 group,X is chlorine or hydrogen; andA.sup.1 is a group of the Formula ##STR3## with the aid of aluminum activated with a catalytic amount of a metal and/or metal salt in a mixture of water, a mineral acid, and an aliphatic carboxylic acid having 1 to 3 carbon atoms at a temperature of 0.degree. to 100.degree. C., thereafter, optionally, the product is recovered from an acid medium at a pH range of 2 to 3 in crystalline form.

Abstract: N,N,N-trimethyl-2-hydroxyethyl-ammonium-[1-ethyl-6-fluoro-4-oxo-7-(1-pipera zinyl)-1,4-dihydro-quinolizine-3-carboxylate] of the formula I ##STR1## as a norfloxacin antimicrobial salt capable of enteral administration.

Abstract: The invention relates to a new and improved process for the preparation of 6-demethyl-6-deoxy-6-methylene-5-oxytetracycline and the 11a-chloro derivative thereof by dehydrating 11a-chloro-5-oxytetracycline-6,12-hemiketal, which comprises treating 11a-chloro-5-oxytetracycline-6,12-hemiketal or an acid salt thereof with a dehydrating mixture formed by the reaction of chloro sulfonic acid and formic acid and isolating the 11a-chloro-6-demethyl-6-deoxy-6-methylene-5-oxytetracycline and salt thus obtained and optionally dehalogenating the same by reaction with a reducing agent.The advantage of the process of the present invention is that it is simple, economical and suitable for industrial scale manufacture and provides a pure product of high quality by excellent yields.

Abstract: A process is disclosed for the preparation of compounds of the Formula IR--X--R.sup.1 (I)wherein X is thio, dithio or carbonyl and R and R.sup.1 are defined hereinbelow which comprises reducing a compound of the Formula IIR--A (II)wherein A is chlorosulfonyl or a group of the Formula ##STR1## with a sulfur compound comprising sulfur which is of the (+)4 oxidation degree and is converted into the (+)6 oxidation degree during the process or with a sulfur compound which is decomposed in acidic medium to a compound of the latter oxidation degree in the presence of a catalytic amount but not more than 0.5 mole--related to 1 mole of the starting material of the Formula II--of elemental iodine or a compound capable of delivering hydrogen iodide in acidic medium or a compound which can be reduced to hydrogen iodide in acidic medium with the sulfur compound used.

Abstract: The invention relates to new 2,3,4-trinor-1,5-inter-m-phenylene-PGI.sub.2 derivatives of the formula (I) ##STR1## wherein A stands for carboxy, cyano, tetrazolyl or --COOR.sup.3 or --CONR.sup.1 R.sup.2 ;R.sup.3 is C.sub.1-4 alkyl or an equivalent of a pharmacologically acceptable cation:R.sup.1 and R.sup.2 each stands for hydrogen, phenyl; C.sub.1-5 alkyl, optionally substituted by carboxy, hydroxy, phenyl or C.sub.2-5 alkoxycarbonyl; or C.sub.1-4 alkylsulfonyl; orR.sup.1 and R.sup.2 together form an .alpha.,.omega.-alkylene chain containing 3-6 carbon atoms;B stands for oxygen or methylene;Y is optionally bromo-substituted vinylene or a --C.tbd.C-- group:R.sup.4 stands for hydrogen or tetrahydro-pyran-2-yl;R.sup.5 represents an alkyl group containing 5-9 carbon atoms, which can be optionally interrupted by one or more oxygen atom(s) or --CH.dbd.CH-- or --C.tbd.

Abstract: Crushing equipment with air-jet, in particular for the comminution of crystalline materials, comprising a cylindrical grinding chamber, nozzles and a nozzle carrying crown. The nozzle carrying crown is assembled of two releasably interconnected crown-halves and an exchangeable wearing ring protecting the outlet opening of the nozzle, and the two crown-halves form the seat of the wearing ring. Useful life of the nozzles of the equipment is practically unrestricted. The nozzles are fit, without a thread, either into one of the crown-halves or between them.

Abstract: 2,6-di-O-methyl-beta-cyclodextrin complexes of compounds of the formula (1a) ##STR1## wherein R.sup.2' stands for C.sub.1 to C.sub.12 alkyl or a group of the formula ##STR2## in which R.sup.11 is C.sub.1 to C.sub.4 alkyl;R.sup.12 is hydrogen or C.sub.1 to C.sub.4 alkyl;n is 0 or 1;p is 1 to 4;r is 1 to 4; andR.sup.3' and R.sup.4' are each C.sub.1 to C.sub.4 alkyl, or pharmaceutically salts thereof are disclosed, having analgesic activity.

Abstract: The invention relates to a new process for separating the four stereoisomers of the cyclopropanecarboxylic acids of the formula ##STR1## wherein R stands for a methyl group or a halogen atom.

Abstract: A process is disclosed for the preparation of a compound of the formula (XI) ##STR1## or a salt thereof, wherein R.sup.1 is hydrogen, halogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.3 alkoxy, or trifluoromethyl;R.sup.5 is amino or C.sub.1 to C.sub.4 alkoxycarbonylamino; andR.sup.4" is C.sub.1 to C.sub.6 alkyl, C.sub.2 to C.sub.6 alkenyl, C.sub.2 to C.sub.6 alkynyl, cyclohexyl, benzyl, or 2-phenyl-ethyl, which comprises the steps of:(a) reacting a compound of the formula (VIII) ##STR2## or a salt thereof, with a basic nucleophilic compound to yield a salt of the formula (IX) ##STR3## wherein R.sup.4' is a lone pair of electrons, in which case an alkali metal or alkali earth metal cation forms a salt with the sulfur atom; and(b) reacting a salt of the formula (IX) with a compound of the formula (X)R.sup.4' --QwhereinQ is hydroxyl, halogen, 1/2SO.sub.4, 1/3PO.sub.3, SO.sub.3 C.sub.6 H.sub.5, or SO.sub.3 C.sub.6 H.sub.4 CH.sub.3 to yield the desired product.

Abstract: The invention relates to new azepino[1,2-a]pyrimidine derivatives--of the general formula ##STR1## wherein p=1, 2 and acid addition salts thereof which can be prepared by(a) reacting a compound of the formula ##STR2## with a compound of the general formula ##STR3## wherein p is as defined above and R.sup.7 is alkoxycarbonyl containing 2 to 5 carbon atoms or carboxamido or(b) reacting a compound of the general formula ##STR4## wherein R.sup.8 is alkyl containing 1 to 4 carbon atoms with a compound of the general formula ##STR5## wherein R.sup.7 is as defined above and if desired converting a compound of the general formula I to acid addition salt thereof or setting it free from the salt thereof.The new compounds show bronchodilatory activity.

Abstract: The invention relates to synergistic antiphlogistic pharmaceutical compositions comprising a pyrido [1,2-a]-pyrimidine derivative of the Formula I ##STR1## wherein R.sup.1 and R.sup.2 are lower alkyl and R.sup.3 stands for lower alkoxycarbonyl or carbamoyl and the dotted line represents an optionally hydrogenated band or a salt or quaternary salt thereof and 1-[p-chloro-benzoly]-2-methyl-5-methoxy-indolyl-3-acetic acid of the Formula II ##STR2## The advantage of the compositions is that as a result of the synergistic activity of the compound of the Formula I, the antiphlogistic Indomethacin of the Formula II can be administered in a significantly lower doses and consequently the unfavorable side effects of the latter compound are mitigated.

Abstract: The invention relates to cyclodextrin polymers swelling quickly and to a great extent in water and a process for the preparation thereof.The cyclodextrin polymers according to the invention contain as additive n-octanol having or glycol derivative or glycerol.The cyclodextrin polymers according to the invention are prepared by reacting cyclodextrin and epichlorohydrin in aqueous alkaline medium. In the reaction the cyclodextrin is reacted with 10 to 20 moles of an alkali hydroxide, 10 to 20 moles of epichlorohydrin and 2 to 8 moles of an alcohol additive, n-octanol, glycol derivative or glycerol calculated on 1 mole of cyclodextrin optionally in the presence of 10 to 15 moles of an organic solvent vaporizing at the reaction temperature or 8 to 12 moles of a high boiling organic solvent assuring heterogeneous phase.